266 related articles for article (PubMed ID: 22014006)
21. Oral cyclophosphamide in recurrent ovarian cancer.
Handolias D; Quinn M; Foo S; Mileshkin L; Grant P; Dutu G; Rischin D
Asia Pac J Clin Oncol; 2016 Mar; 12(1):e154-60. PubMed ID: 23718870
[TBL] [Abstract][Full Text] [Related]
22. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
Garcia AA; Hirte H; Fleming G; Yang D; Tsao-Wei DD; Roman L; Groshen S; Swenson S; Markland F; Gandara D; Scudder S; Morgan R; Chen H; Lenz HJ; Oza AM
J Clin Oncol; 2008 Jan; 26(1):76-82. PubMed ID: 18165643
[TBL] [Abstract][Full Text] [Related]
23. Incorporation of pazopanib in maintenance therapy of ovarian cancer.
du Bois A; Floquet A; Kim JW; Rau J; del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Kimmig R; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Mouret-Reynier MA; Kim JH; Kurzeder C; Lesoin A; Vasey P; Marth C; Canzler U; Scambia G; Shimada M; Calvert P; Pujade-Lauraine E; Kim BG; Herzog TJ; Mitrica I; Schade-Brittinger C; Wang Q; Crescenzo R; Harter P
J Clin Oncol; 2014 Oct; 32(30):3374-82. PubMed ID: 25225436
[TBL] [Abstract][Full Text] [Related]
24. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Coleman RL; Handley KF; Burger R; Molin GZD; Stagg R; Sood AK; Moore KN
Gynecol Oncol; 2020 May; 157(2):386-391. PubMed ID: 32037195
[TBL] [Abstract][Full Text] [Related]
25. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.
Matei D; Emerson RE; Schilder J; Menning N; Baldridge LA; Johnson CS; Breen T; McClean J; Stephens D; Whalen C; Sutton G
Cancer; 2008 Aug; 113(4):723-32. PubMed ID: 18618737
[TBL] [Abstract][Full Text] [Related]
26. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
27. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
Tillmanns TD; Lowe MP; Walker MS; Stepanski EJ; Schwartzberg LS
Gynecol Oncol; 2013 Feb; 128(2):221-8. PubMed ID: 22960352
[TBL] [Abstract][Full Text] [Related]
28. A retrospective, real-life analysis of metronomic oral single-agent cyclophosphamide for the treatment of platinum-pretreated advanced ovarian carcinoma in Italy.
Gebbia V; Martorana F; Scandurra G; Valerio MR; Cufari S; Vigneri P; Sanò MV; Scollo P
J Oncol Pharm Pract; 2024 Jul; 30(5):853-859. PubMed ID: 37501558
[TBL] [Abstract][Full Text] [Related]
29. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
Merritt WM; Nick AM; Carroll AR; Lu C; Matsuo K; Dumble M; Jennings N; Zhang S; Lin YG; Spannuth WA; Kamat AA; Stone RL; Shahzad MM; Coleman RL; Kumar R; Sood AK
Mol Cancer Ther; 2010 Apr; 9(4):985-95. PubMed ID: 20371710
[TBL] [Abstract][Full Text] [Related]
30. Long-term remission in a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and metronomic cyclophosphamide treatment.
Aigner J; Bischofs E; Hallscheidt P; Sohn C; Schneeweiss A; Eichbaum M
Anticancer Drugs; 2011 Nov; 22(10):1030-3. PubMed ID: 21970854
[TBL] [Abstract][Full Text] [Related]
31. A review and metanalysis of metronomic oral single-agent cyclophosphamide for treating advanced ovarian carcinoma in the era of precision medicine.
Martorana F; Scandurra G; Valerio MR; Cufari S; Vigneri P; Sanò MV; Scibilia G; Scollo P; Gebbia V
J Oncol Pharm Pract; 2024 Jan; 30(1):173-181. PubMed ID: 38018146
[TBL] [Abstract][Full Text] [Related]
32. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
Matulonis UA; Berlin S; Ivy P; Tyburski K; Krasner C; Zarwan C; Berkenblit A; Campos S; Horowitz N; Cannistra SA; Lee H; Lee J; Roche M; Hill M; Whalen C; Sullivan L; Tran C; Humphreys BD; Penson RT
J Clin Oncol; 2009 Nov; 27(33):5601-6. PubMed ID: 19826113
[TBL] [Abstract][Full Text] [Related]
33. [
Sharma R; Valls PO; Inglese M; Dubash S; Chen M; Gabra H; Montes A; Challapalli A; Arshad M; Tharakan G; Chambers E; Cole T; Lozano-Kuehne JP; Barwick TD; Aboagye EO
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1239-1251. PubMed ID: 31754793
[TBL] [Abstract][Full Text] [Related]
34. Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer.
Jurado JM; Sánchez A; Pajares B; Pérez E; Alonso L; Alba E
Clin Transl Oncol; 2008 Sep; 10(9):583-6. PubMed ID: 18796376
[TBL] [Abstract][Full Text] [Related]
35. Treatment of recurrent ovarian cancer.
Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
[TBL] [Abstract][Full Text] [Related]
36. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
37. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
38. Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ).
Chekerov R; Arndt T; Pietzner K; Canzler U; Wimberger P; Strauß HG; Mahner S; Woelber L; de Gregorio N; Stocker G; von Abel E; Neunhoeffer T; Belau AK; Mustea A; Yalinkaya I; Braicu EI; Richter R; Sehouli J;
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7637-7649. PubMed ID: 37000264
[TBL] [Abstract][Full Text] [Related]
39. A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Duska LR; Petroni GR; Varhegyi N; Brown J; Jelovac D; Moore KN; McGuire WP; Darus C; Barroilhet LM; Secord AA
Gynecol Oncol; 2020 Jun; 157(3):585-592. PubMed ID: 32247603
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer.
Hasan J; Ton N; Mullamitha S; Clamp A; McNeilly A; Marshall E; Jayson GC
Br J Cancer; 2005 Sep; 93(6):647-51. PubMed ID: 16222310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
